Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: belimumab Clear all
Active, not recruiting Phase 4 Interventional

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

NCT06411249
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab (GSK1550188)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
41
States / cities
Anniston, Alabama • Flagstaff, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

NCT00732940
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 100 mg SC
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Birmingham, Alabama • Long Beach, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 25, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional Results available

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

NCT04767698
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

NCT00583362
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 25, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional Results available

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

NCT00583557
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
belimumab
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 25, 2026, 10:32 PM EDT
Completed No phase listed Observational

Belimumab (BENLYSTA®) Pregnancy Registry

NCT01532310
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 25, 2026, 10:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

NCT04179032
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
No Longer Available No phase listed Expanded access

Compassionate Use for Subcutaneous (SC) Belimumab

NCT03125486
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
SC belimumab 200 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 25, 2026, 10:32 PM EDT
Recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Belimumab, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99

NCT00931086
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
belimumab
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

NCT00410384
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
67
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Belimumab for Lupus Nephritis

NCT02260934
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 25, 2026, 10:32 PM EDT
Recruiting Phase 1 Interventional

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

NCT04097561
View directory record Official record
Conditions
Idiopathic CD4 Lymphopenia
Interventions
Belimumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 10 mg/kg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00657007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab, Placebo
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Results available

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

NCT03207958
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease
Interventions
Belimumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
Recruiting Phase 4 Interventional

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

NCT07611214
View directory record Official record
Conditions
Lupus Nephritis
Interventions
LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid
Drug · Biological
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
27
States / cities
La Mesa, California • Los Alamitos, California • Arvada, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

NCT00724867
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 1 mg/kg, Belimumab 10 mg/kg
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2016 · Synced Sep 25, 2026, 10:32 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852
View directory record Official record
Conditions
Glomerulonephritis, Membranous
Interventions
Belimumab 10 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Belimumab in Idiopathic Inflammatory Myositis

NCT02347891
View directory record Official record
Conditions
Myositis
Interventions
Belimumab, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00071487
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 25, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects

NCT01894360
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 200 mg/mL
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 25, 2026, 10:32 PM EDT
Completed No phase listed Observational Results available

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

NCT01729455
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Benlysta, Standard of Care (SoC) Therapy
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
3,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
102
States / cities
Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 25, 2026, 10:32 PM EDT